Posted by Michael Wonder on 28 Dec 2021
ICER to assess treatments for Alzheimer’s disease
22 December 2021 - Report will be subject of CTAF meeting in July 2022; draft scoping document open to public comment until 19 January 2022.
The Institute for Clinical and Economic Review announced today that it will assess the comparative clinical effectiveness and value of donanemab (Eli Lilly) and lecanemab (Eisai) for the treatment of Alzheimer’s disease, along with aducanumab (Aduhelm, Biogen) should new clinical evidence be available.
